

Knobbe Martens Olson & Bear LLP

Intellectual Property Law

RECEIVED
CENTRAL FAX CENTER

2040 Main Street
Fourteenth Floor
Irvine, CA 92614
Tel 949-760-0404
Fax 949-760-9502
www.kmob.com

FEB 22 2006

FACSIMILE TRANSMITTAL SHEET

CONFIRMATION COPY WILL FOLLOW VIA:

<input type="checkbox"/> MAIL	<input checked="" type="checkbox"/> WILL NOT FOLLOW
<input type="checkbox"/> INTERNATIONAL AIRMAIL	<input type="checkbox"/> HAND DELIVERY
<input type="checkbox"/> COURIER	<input type="checkbox"/> WITH ENCLOSURES
<input type="checkbox"/> E-MAIL	<input type="checkbox"/> WITHOUT ENCLOSURES

Confidentiality Notice:

The documents accompanying this facsimile transmission contain confidential information which may be legally privileged. The information is intended only for the use of the recipient named below. If you have received this facsimile in error, please immediately notify us by telephone to arrange for return of the original documents to us; and any disclosure, copying, distribution or the taking of any action in reliance on the contents of this fixed information is strictly prohibited.

To: Susan Ungar
 FIRM: USPTO
 FACSIMILE No.: (571)273-0837
 OUR Ref.: BOEHM22.001APC
 YOUR Ref.: 10/019,513
 FROM: Che Chereskin
 OPERATOR: Deirdre Bailey
 DATE: February 22, 2006

NO. OF PAGES: 20 (incl. cover sheet)
 TIME:

IF YOU DID NOT RECEIVE ALL OF THE PAGES PLEASE CALL BACK IMMEDIATELY
 OPERATOR PHONE No.: (949) 760-0404 FACSIMILE NO.: (949) 760-9502

MESSAGE: FOLLOW UP TO TELEPHONE CONVERSATION

2392473
 022206

San Diego
 619-235-8550

San Francisco
 415-954-4114

Los Angeles
 310-551-3450

Riverside
 951-781-9231

San Luis Obispo
 805-547-5588

RECEIVED
CENTRAL FAX CENTER

FEB 22 2006

BOEHM21.001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Brossart, et al.
Appl. No.	:	10/019,513
Filed	:	August 6, 2002
For	:	PEPTIDE FOR TRIGGERING AN IMMUNE REACTION AGAINST TUMOR CELLS
Examiner	:	Ungar, Susan
Group Art Unit	:	1642

LETTER

February 22, 2006

Dear Examiner Ungar

Further to our telephone conversation this morning, please find attached an Inventor's Declaration with Exhibits A & B which provide data showing the utility of the claimed invention in the diagnosis of cancer in vitro. As discussed in the Declaration and accompanying Exhibit B (particularly Figure 4), the STAPPVHNV peptide (SEQ ID NO: 1) successfully lysed primary cancer cells.

We gratefully acknowledge the indication that claim 1 is allowable and that claim 2 is also allowable after Examiner's amendment. We respectfully submit, that in view of the attached Declaration and Exhibits A & B, that claims 21, 24, 27, 29, and 31 may be rejoined and allowed.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Feb. 22, 2006

By: Che S. Chereskin
 Che Swyden Chereskin, Ph.D.
 Registration No. 41,466
 Agent of Record
 Customer No. 20,995
 (949) 760-0404

2392378/032206